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Abstract
Background: The recent increase in bacterial resistance to antibiotics has promoted the exploration of novel
antibacterial materials. As a result, many researchers are undertaking work to identify new lantibiotics because of
their potent antimicrobial activities. The objective of this study was to provide details of a lantibiotic-like gene
cluster in Paenibacillus elgii B69 and to produce the antibacterial substances coded by this gene cluster based on
culture screening.
Results: Analysis of the P. elgii B69 genome sequence revealed the presence of a lantibiotic-like gene cluster
composed of five open reading frames (elgT1, elgC, elgT2, elgB, and elgA). Screening of culture extracts for active
substances possessing the predicted properties of the encoded product led to the isolation of four novel peptides
(elgicins AI, AII, B, and C) with a broad inhibitory spectrum. The molecular weights of these peptides were 4536,
4593, 4706, and 4820 Da, respectively. The N-terminal sequence of elgicin B was Leu-Gly-Asp-Tyr, which
corresponded to the partial sequence of the peptide ElgA encoded by elgA. Edman degradation suggested that
the product elgicin B is derived from ElgA. By correlating the results of electrospray ionization-mass spectrometry
analyses of elgicins AI, AII, and C, these peptides are deduced to have originated from the same precursor, ElgA.
Conclusions: A novel lantibiotic-like gene cluster was shown to be present in P. elgii B69. Four new lantibiotics
with a broad inhibitory spectrum were isolated, and these appear to be promising antibacterial agents.
Background
Bacteriocins are ribosomally synthesized antibacterial
peptides produced by bacteria that possess inhibitory
activity against closely related species. Two major types
of bacteriocins can be distinguished according to their
posttranslational modifications: Class I, the modified
bacteriocins or lantibiotics, and Class II, the unmodified
bacteriocins. Lantibiotics are a group of small (< 5 kDa)
modified bacteriocins characterized by the presence of
unusual amino acids such as the thioether-bridge-con-
taining amino acids lanthionine (Lan) and methyl-
lanthionine (MeLan), and several dehydrated amino
acids such as a,b-didehydroalanine (Dha) and a,b-dide-
hydrobutyrine (Dhb). Most lantibiotics show broad anti-
bacterial activity. For instance, nisin, a safe food
preservative [1], displays potent activity against Gram-
positive bacteria, including spoilage and pathogenic bac-
teria such as Bacillus cereus, Listeria monocytogenes,
Enterococcus, Staphylococcus,a n dStreptococcus [2].
However, some peptides (notably lantipeptides contain-
ing Lan and MeLan residues) such as SapB [3] show no
antibacterial activity.
Lantibiotics are synthesized as prepeptides that consist
of an N-terminal leader sequence and a propeptide part;
these prepeptides subsequently undergo posttransla-
tional modifications to become the mature antibiotic.
The formation of Lan and MeLan are attributed to the
intermolecular cyclization of the thiol groups of cysteine
residues with Dha and Dhb, which are obtained from
the dehydration of serine and threonine residues,
respectively. Dedicated biosynthetic enzymes are
required during the process of maturation and the genes
encoding these proteins are clustered, as described for
nisin [4,5], pep5 [6], nukacin ISK-1 [7], epicidin 280 [8],
and mersacidin [9]. According to the genetic
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any medium, provided the original work is properly cited.organization of lantibiotics, they can be divided into sev-
eral types [10,11]. The typical gene cluster of type AI
lantibiotics, such as nisin and epidermin, includes the
structural gene lanA, modification enzyme-encoding
genes lanB and lanC, the processing protease-encoding
gene lanP, the transporter gene lanT, and the immunity
genes lanI and/or lanEFG. However, not all type AI lan-
tibiotic-like gene clusters contain all these genes; for
example, in the gene cluster spaBTCAIFGRK [12],
which codes for the biosynthesis of subtilin, the function
of LanP is replaced by an intrinsic protease of Bacillus
subtilis ATCC 6633 [13].
Much attention has been concentrated on the identifi-
cation of new lantibiotics because of their potent antimi-
crobial activities. In recent years, with the availability of
abundant genomic sequence data in public databases,
many new lantibiotics and lantipeptides such as Bsa,
lichenicidin, and a range of cyanobacteria-associated lan-
tipeptides [14-16] have been identified. For example, the
bacterial genus Paenibacillus is known for its ability to
produce peptide antibiotics [17-19], and an increasing
number of Paenibacillus spp. genomes have been
sequenced, revealing several novel lantibiotic-related
gene clusters [20,21]. However, to date, only one novel
lantibiotic, paenibacillin, produced by Paenibacillus
polymyxa OSY-DF [22] has been reported. In the pre-
sent study, we present the detailed bioinformatic analy-
sis of a novel lantibiotic-like gene cluster in the
Paenibacillus elgii B69 genome. Screening of bacterial
cultures, mass spectrometry (MS) analysis, and N-term-
inal amino acid sequencing were used to confirm that
the P. elgii B69 gene cluster encodes elgicins, novel
broad-spectrum lantibiotics.
Results and discussion
Putative lantibiotic-like gene cluster of P. Elgii B69
P. elgii B69 was subjected to whole-genome shotgun
sequencing, yielding 7.9 Mb of sequence on 278
assembled contigs [23]. Data mining for the LanC
homolog amidst the genomic data of P. elgii B69, using
t h eS p a Cs e q u e n c eo fP. polymyxa E681 as a driver,
resulted in the identification of a lantibiotic-like gene
cluster containing five probable open reading frames
(ORFs), designated elgT1, elgC, elgT2, elgB,a n delgA
(Figure 1A). All genes, except elgT1, were transcribed in
the same orientation. The amino acid sequences of the
four products of the elg gene (elgT1CT2B) showed high
levels of identity (31%-38%) with those of homologous
proteins from several type AI lantibiotic gene clusters
(Table 1).
ElgT1 (596 amino acids (a.a.)) and ElgT2 (625 a.a.)
showed high-level identity with numerous adenosine-5’-
triphosphate (ATP)-binding cassette (ABC) transporter
proteins. ElgT1 shared 31% identity with SpaT, a protein
responsible for the transportation of the ericins A and S
of B. subtilis A1/3 [GenBank: AAL15565] [12], and 31%
identity with EtnT, which is responsible for the export
of the entianin of B. subtilis subsp. spizizenii DSM
15029
T [GenBank: AEK64492] [24]. Similarly, ElgT2
showed strong homology (38% identity) with the subti-
lin-transport protein of B. subtilis ATCC 6633 [Gen-
Bank: P33116] [25], and was homologous to NisT of
Lactococcus lactis N8 [GenBank: CAA79469] and NsuT
of Streptococcus uberis 42 [GenBank: ABA00880] (34%
identity in both cases). These proteins are responsible
for the transportation of nisin Z and nisin U, respec-
tively [26,27]. The two proteins ElgT1 and ElgT2 also
shared 28% sequence identity with each other, suggest-
ing that they have similar functions in the processes of
transportation and secretion of elgicins. ElgT1 and
ElgT2 may serve as a two-component ABC transporter,
similar to MibTU and CinTU, which are probably
involved in the export of microbisporicin and cinnamy-
cin [28,29]; however this function is uncommon in the
maturation of lantibiotics.
ElgC encodes a protein containing 454 amino acids,
which shows strong homology to the lantibiotic cyclase,
MibC, of Microbispora corallina NRRL 30420 (33%
identity) [GenBank: ADK32556]. MibC is involved in
the formation of (Me)Lan bridges in microbisporicin
[28]. The amino acid sequences encoded by the lanC
genes have some conserved structural motifs, including
GXAHG, WCXG, and CHG, in which the cysteine and
histidine residues are highly conserved [30]. The align-
ment of ElgC with several type AI lantibiotic synthetases
showed that ElgC contains several conserved sequences,
such as GVSHG (positions 244-248), WCYG (positions
316-319), and CHG (positions 366-368), wherein
His247, Cys317, Cys366, and His367 are strictly con-
served. These observations indicate that ElgC is a lanti-
biotic synthetase that catalyzes the synthesis of Lan and
MeLan residues.
A large ORF upstream and overlapping elgT2 by 4 bp
encodes a protein of 1037 amino acids. The putative
protein ElgB shares 31% identity with MibB of M. coral-
lina NRRL 30420 [GenBank: ADK32555] and 30% iden-
tity with SpaB of B. subtilis ATCC 6633 [GenBank:
P39774]. The proteins MibB and SpaB are responsible
for the dehydration of serine and threonine residues in
the propeptide to form the unsaturated amino acids of
microbisporicin and subtilin, respectively [28,31]. Thus,
ElgB appears to be a dehydratase involved in the process
of maturation.
Similarly, elgA encodes the prepeptide of the elgicins,
with a length of 64 amino acids. No lantibiotics reported
thus far share homology with ElgA, suggesting that the
mature proteins derived from ElgA are novel lantibio-
tics. The alignment of the putative leader peptide of
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Page 2 of 9ElgA with those of other lantibiotics revealed the exis-
tence of a possibly conserved motif “FDLD” (Figure 1C),
which resembles the “FDLN” motif in the leader peptide
of type AI lantibiotics [32]. Considering that the elg
gene cluster contains the lanB and lanC genes encoding
the modified enzymes, it could be concluded that the
elgicins are type AI lantibiotics.
The elg gene cluster lacks the immunity genes lanI
and lanEFG.L a n E F Ga c t sa sa nA B Ct r a n s p o r t e rf o r
lantibiotic immunity; for example, NisEFG expels lanti-
biotic molecules that have entered the cytoplasmic
membrane into the extracellular environment [33]. Con-
sidering the mechanism of LanEFG-imparted immunity,
ElgT1T2 is likely to play a role in self-protection, in
addition to that of secretion and transportation of the
elgicins.
The leader peptides of type AI lantibiotics are usually
p r o c e s s e db yas e r i n ep r o t e a s ee n c o d e db ylanP,w h i c h
is not found in the elg gene cluster. The leader peptide
of ElgA may instead be processed by an intrinsic B69
serine protease. This elgicin maturation process might
therefore resemble that of subtilin, wherein the leader
peptide of presubtilin is removed by an intrinsic B. sub-
tilis subtilisin-like protease [13].
Isolation and purification of elgicins
Genomic analysis of P. elgii B69 revealed the presence of
a new lantibiotic-like gene cluster. To express this elg
gene cluster, P. elgii B69 was grown aerobically at 30°C
for 120 h in different fermentation media designed for
the production of active substances. At harvest, extrac-
tions of B69 fermentation broths were achieved using
column chromatographic fractionation on AB-8 macro-
porous resin (Haiguang Chemical Ltd., Tianjin, China).
The KL medium fraction (5 g/L glucose, 4 g/L (NH4)
2SO4,2 . 6g / LK 2HPO4, 4 g/L MgSO4, 2 g/L NaCl, 2 g/L
Figure 1 Elg gene cluster, ElgA amino acid sequence and sequence alignment with type AI prelantibiotics. A, The biosynthetic gene
cluster of P. elgii B69 consists of five ORFs, elgT1, elgC, elgT2, elgB, and elgA. The number of amino acids encoded by each gene is indicated
below each locus, and the arrows indicate the relative directions of transcription. B, The amino acid sequence of the prepeptide ElgA. C,
Sequence alignment of the deduced pre-elgicin (ElgA) with type AI prelantibiotics of nisin (NisA), subtilin (SpaS), epidermin (EpiA), and Pep5
(PepA). The conserved residues are shaded and the cleavage sites of the processing protease are symbolized by vertical solid arrows. The
resulting propeptide of the cleaved ElgA in the figure is elgicin C (underlined). ElgA is a type AI prelantibiotic because of the conserved motif
“FDLD” in its leader peptide segment and the presence of the genes elgB and elgC.
Table 1 Deduced peptides and proteins derived from the elg gene cluster
ORF Size of Putative
Protein (aa)
Putative Function Sequence Homolog (GenBank ID) Identities (%; No. of
amino acids)
elgT1 596 Transportation and secretion,
ABC transporter
Putative SpaT, Bacillus subtilis A1/3, AAL15565 31; 614
elgC 454 Synthetase in posttranslational
modification
Lantibiotic cyclase MibC, Microbispora corallina NRRL 30420,
ADK32556
36; 485
elgT2 625 Transportation and secretion,
ABC transporter
Subtilin transport ATP-binding protein SpaT, Bacillus subtilis
ATCC 6633, P33116
38; 614
elgB 1037 Dehydration of serine and
threonine
Lantibiotic dehydratase MibB, Microbispora corallina NRRL
30420, ADK32555
31; 1115
elgA 64 Elgicins PREDICTED: similar to HECT, C2, and WW domain, containing
E3 ubiquitin, XP_001507682
59; 1657
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Page 3 of 9CaCl2,2m g / LF e S O 4·7H2O, 2 mg/L ZnSO4·7H2O, and
1.5 mg/L MnSO4·H2O, pH 7.2) eluted by 80% methanol
showed activity against the indicator strain P. ehimensis.
This fraction was then applied to the solid-phase extrac-
tion (SPE) column. The fraction with activity against the
indicator strain was eluted with 50% methanol and
further separated by analytical reverse-phase high-per-
formance liquid chromatography (RP-HPLC). Aided by
the presence of several tyrosine residues within the pre-
cursor peptide ElgA, its ultraviolet (UV) absorption was
measured at 280 nm during analytical HPLC. The frac-
tions corresponding to the retention time of 21.290-
22.036 min were isolated, and they showed activity
against P. ehimensis.
Large-scale fermentation of P. elgii B69 was carried
out in KL medium for the production of active sub-
stances. The target compounds were then isolated by a
simple three-step purification procedure consisting of
AB-8 resin fractionation, SPE, and preparative RP-
HPLC, as described in the “Methods” section. In the
preparative RP-HPLC profile, the three peaks corre-
sponding to retention times of 34.21, 35.43, and 36.53
min (Figure 2) were pooled and designated elgicin A, B,
and C, respectively, of which elgicin B was the major
component. These fractions were lyophilized and sub-
jected to electrospray ionization-mass spectrometry
(ESI-MS) for molecular analyses.
ESI-MS analyses of elgicins
To determine the molecular masses of elgicins, the lyo-
philized elgicins A, B, and C were dissolved in sterile
water and subjected to ESI-MS. The MS spectrum of
HPLC-purified elgicin A revealed four signals at the
mass-to-charge ratios (m/z) 1135.07 [M + 4H]
4+,
1512.89 [M + 3H]
3+, 1149.31 [M + 4H]
4+, and 1532.58
[M + 3H]
3+ (Figure 3A). The molecular weight calcu-
lated from the two former signals was 4536 Da, and the
others corresponded to a molecular weight of 4593 Da.
These findings suggest that Peak 1 contained two com-
pounds, designated elgicin AI and elgicin AII. The mole-
cular weight of elgicin AII was 57 Da larger than that of
elgicin AI; this difference corresponds to the molecular
weight of a single glycine residue. In the case of Peak 2,
the mass spectrum showed the presence of two strong
signals at m/z values of 1177.72 [M + 4H]
4+ and
1569.89 [M + 3H]
3+, corresponding to a molecular mass
of 4706 Da (Figure 3B). The molecular weight of elgicin
Bw a s1 1 3D al a r g e rt h a nt h a to fA I I ;t h i sd i f f e r e n c e
corresponds to the molecular mass of a single leucine
residue, as deduced from the prepeptide of ElgA that
lacks an isoleucine residue (Figure 1B). Compound elgi-
cin C, with a retention time of 36.53 min, had a molecu-
lar mass of 4820 Da, consistent with the two signals at
m/z 1206.14 [M + 4H]
4+ and 1608.30 [M + 3H]
3+ (Fig-
ure 3C). The molecular mass of elgicin C was 114 Da
larger than that of elgicin B; this difference is consistent
with the molecular mass of a single asparagine residue.
Lantibiotics have small molecular weights (< 5 kDa)
that usually range from 1700-4000 Da. Thus far, the
molecular weights of only two lantibiotics, cytolysin LL
(isolated from the Enterococcus faecalis strain FA2-2)
and carnocin U149 (produced by Carnobacterium pisci-
cola U149), exceed 4 kDa (4164 and 4635 Da, respec-
tively) [10]. Our newly isolated four-component elgicins
therefore have unusually large molecular weights of
4536 Da (elgicin AI), 4593 Da (elgicin AII), 4706 Da
(elgicin B), and 4820 Da (elgicin C). To the best of our
knowledge, no other lantibiotics have molecular weights
greater than those of elgicins B and C.
Analysis of N-terminal amino acid sequence
To confirm whether the four-component antibacterial
agents are derived from ElgA, HPLC-purified elgicin B
was subjected to automated Edman degradation to
determine its N-terminal amino acid sequence (Figure
4). The first four amino acids were Leu-Gly-Asp-Tyr.
The fifth residue was blocked completely, suggesting the
presence of a dehydrated amino acid residue, a charac-
teristic feature of lantibiotics. The Leu-Gly-Asp-Tyr
sequence was consistent with the sequence of the pro-
peptide that resulted from the removal of the leader
peptide after cleavage at positions ranging between
Asp21 and Leu22 of ElgA (Figure 1B). The observed
molecular weight of elgicin B was 144 Da smaller than
the calculated molecular weight of the unmodified pro-
peptide, which can be explained by the loss of eight
Figure 2 Reverse-phase HPLC profile of crude SPE-extraction.
UV absorption was measured at 280 nm. MV, millivolt. Peak 1, with
retention time of 34.21 min, corresponds to elgicins AI and AII.
Peaks 2 and 3, with retention times of 35.43 and 36.53 min,
correspond to elgicins B and C, respectively.
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Page 4 of 9Figure 3 ESI-MS of RP-HPLC-purified elgicins AI, AII, B, and C isolated from fermentation medium. A, Peaks at 1512.89 [M + 3H]
3+ and
1135.07 [M + 4H]
4+ correspond to a mass of 4536 Da for elgicin AI. Peaks at 1532.58 [M + 3H]
3+ and 1149.31 [M + 4H]
4+ correspond to a mass
of 4593 Da for elgicin AII, indicating that it has one Gly residue more than elgicin AI. B, Peaks at 1569.89 [M + 3H]
3+ and 1177.72 [M + 4H]
4+
correspond to a mass of 4706 Da for elgicin B, indicating that it has one Leu residue more than elgicin AII. C, Peaks at 1608.30 [M + 3H]
3+ and
1206.14 [M + 4H]
4+ correspond to a mass of 4820 Da for elgicin C, indicating that it has one Asn residue more than elgicin B.
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Therefore, elgicin B is deduced to be the posttransla-
tional modified product of ElgA.
The residue at position 21 of ElgA (Figure 1B) was
asparagine and leucine was found at position 22. Con-
sidering the ESI-MS results, wherein the molecular
weight of elgicin C was 114 Da larger and that of elgicin
AII 113 Da smaller than that of elgicin B, the N-term-
inal amino acid sequences of the unmodified propep-
tides of elgicins C and AII could be Asp-Leu-Gly-Asp-
Tyr and Gly-Asp-Tyr, respectively. Similarly, because
the glycine residue was at position 23 of ElgA and the
molecular weight of elgicin AI was 57 Da smaller than
that of elgicin AII, the N-terminal amino acid sequence
of the unmodified propeptide of elgicin AI could be
Asp-Tyr. The observed molecular weights of these three
peptides were 144 Da smaller than the calculated mole-
cular weights of the respective predicted propeptides.
This finding may be attributed to the loss of eight H2O
molecules during maturation. Elgicins AI, AII, and C
were thus confirmed to be the modified products of
ElgA, that is, these four antibacterial agents possibly ori-
ginated from the same prepeptide, ElgA, by peptide
cleavage, followed by the removal of one amino acid at
each N-terminal.
In the elg gene cluster, the presence of elgB, elgC,a n d
the leader peptide of ElgA containing the motif “FDLD”
confirmed that the elgicins are type AI lantibiotics. The
origin of elgicins from identical pre-peptides by peptide
cleavage and the removal of one amino acid from each
corresponding N-terminus could be achieved in two
ways. First, the serine protease could cleave at four clea-
vage sites of ElgA, that is, Ala20-Asp21, Asp21-Leu22,
Leu22-Gly23, and Gly23-Asp24 (Figure 1B), resulting in
the simultaneous production of these four peptides. Sec-
ond, the Ala20-Asp21 could be cleaved by the serine
protease to produce elgicin C, followed by the successive
protease removal of Asp21, Leu22, or Gly23 residues
from elgicin C to yield elgicins B, AII, and AI,
respectively.
Antimicrobial activity of elgicins
Preparative RP-HPLC-purified elgicin compounds (150
μg) were pipetted onto a sterile paper disk and tested
for antibacterial activity against various bacterial strains.
As shown in Table 2, the active substances produced by
Figure 4 Determination of N-terminal sequence of elgicin B using standard Edman degradation method. A, The 20 known amino acids
served as standards. The peak representing the cysteine residue was not labeled. B-E, The first four amino acids in the N-terminal region of
elgicin B (leucine, glycine, asparagine, and tyrosine) were determined. Diphenylthiourea (dptu) is the by-product of the Edman degradation
reaction.
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Page 6 of 9P. elgii B69 showed inhibitory activity toward Staphylo-
coccus epidermidis CMCC 26069, Staphylococcus aureus
ATCC 43300, Pseudomonas aeruginosa ATCC 27853,
Escherichia coli ATCC 35218, and Proteus vulgaris
CMCC 49027. Other tested strains, namely, S. aureus
ATCC 25923 and B. subtilis CGMCC 1.1470, were resis-
tant to elgicins.
Conclusions
Genomic sequence analysis of Paenibacillus elgii B69
showed a novel lantibiotic-like gene cluster. Four new
lantibiotics, designated elgicins AI, AII, B, and C, were
isolated from the KL medium. To the best of our
knowledge, elgicins B and C are the largest reported lan-
tibiotics to date, with molecular weights of 4706 and
4820 Da, respectively. Elgicins have broad inhibitory
activities against several Gram-positive and Gram-nega-
tive bacteria. Further studies are required to determine
their structures, identify their mechanisms of action,
and find suitable bioprocessing strategies for efficient
elgicin production.
Methods
Bacteria and culture conditions
P. elgii B69 was isolated from a soil sample collected
from Hangzhou, China [19]. Nutrient broth was routi-
nely used for culturing P. elgii B69 at 30°C for 24 h.
The active substances were produced in synthetic med-
i u m( K L ) .A b o u t2 5m Lo ft h eP. elgii B69 culture was
used to inoculate 2-L conical flasks, each containing 500
mL of KL medium. Four other fermentation media,
Landy medium (20 g/L glucose, 5 g/L L-glutamic acid,
0.5 g/L MgSO4,0 . 5g / LK C l ,1g / LK H 2PO4,0 . 1 5m g / L
Fe(SO4)3·6H2O, 5.0 mg/L MnSO4·H2O, and 0.16 mg/L
CuSO4·5H2O) [34], MYPGP broth (15 g/L yeast extract,
10 g/L Mueller-Hinton broth, 2 g/L glucose, 3 g/L
K2HPO4, and 1 g/L sodium pyruvate) [35], AK medium
(0.5 g/L asparagine, 0.5 g/L K2HPO4, 0.2 g/L MgSO4,
0.01 g/L FeSO4·7H2O, and 10 g/L glucose), and Luria-
Bertani (LB) medium, were used to test for the presence
of inhibitory factors.
The fermentation batches were incubated aerobically
on a shaker (200 rpm) at 30°C for 120 h. The test
strains used to determine sensitivity to elgicins included
S. epidermidis CMCC 26069, S. aureus ATCC 43300, S.
aureus ATCC 25923, B. subtilis CGMCC 1.1470, P. aer-
uginosa ATCC 27853, E. coli ATCC 35218, and P. vul-
garis CMCC 49027. P. ehimensis, a closely related
species of P. elgii, was used as the indicator strain. All
test stains were grown in nutrient broth or nutrient agar
plates at 37°C. For stock preparation, the cells were cul-
tivated for 24 h, mixed with sterile glycerol (to a final
concentration of 25%, v/v), and stored at -80°C.
Bioinformatic analyses
Using the modification enzyme SpaC of P. polymyxa
E681 [GenBank: YP_003869828] as a driver sequence,
the draft genome sequence of P. elgii B69 was examined
for homology using the basic local alignment search tool
(BLAST). The ORFs of the gene cluster were identified
using an ORF finder http://www.ncbi.nlm.nih.gov/gorf/
gorf.html. Amino acid sequence identities of the pro-
teins were identified by searching the National Center
for Biotechnology Information (NCBI) database using
BLAST. Alignment was carried out using MEGA 4.0.1
software [36].
Isolation and purification of elgicins
Stationary-phase cells were removed from the 3-L fer-
mentation medium by centrifugation at 5000 rpm for 30
min at 4°C. The cell-free supernatant was loaded onto
an AB-8 macroporous absorption resin column preequi-
librated with distilled water. The column was washed
sequentially with distilled water, followed by elution
with 20% and 80% (v/v) methanol. All fractions, except
those eluted with 80% methanol, were discarded. The
80% methanol fraction was pooled and concentrated at
45°C using a rotary evaporator. The resulting contents,
which totaled approximately 70 mL, were centrifuged at
7000 rpm for 30 min at 4°C. The supernatant was
applied to a C18 SPE column (Hardwee, Germany) pre-
treated with distilled water. The column was washed
with three bed volumes of distilled water, followed by
three bed volumes of 30% methanol. These fractions
were discarded. The fraction containing the active sub-
stances was recovered from the column by washing with
two bed volumes of 50% methanol and concentrated by
vacuum evaporation at 45°C.
Aliquots (12 mL) of this material were further sepa-
rated by preparative reverse-phase high-pressure liquid
chromatography (RP-HPLC), in a system equipped with
a YMC-pack ODS-A C18 (5 μm, 250 mm × 20 mm) col-
umn. Eluent A was MilliQ-purified water containing
Table 2 Antibacterial spectra of RP-HPLC-purified elgicin
compounds
Indicator Strain Diameter of Inhibition (mm)
Elgicins
a Polymyxin B
b
Staphyloccus epidermidis CMCC 26069 8 18
Staphylococcus aureus ATCC 43300 8 15
Staphylococcus aureus ATCC 25923 0 0
Bacillus subtilis CGMCC 1.1470 0 10
Pseudomonas aeruginosa ATCC 27853 7 12
Escherichia coli ATCC 35218 9 10
Proteus vulgaris CMCC 49027 8 0
aThe amount of elgicins is 150 μg per disk.
bThe amount of polymyxin B is 30 μg per disk.
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eluent B. Elution was carried out at a flow rate of 10
mL/min using a constant gradient of 20% eluent B for
15 min, followed by a linear gradient of eluent B ranging
from 20-35% over a period of 30 min. The process was
detected spectrophotometrically by measuring the
absorption values at 280 nm. The fractions containing
the elgicins were collected, concentrated, and lyophilized
to give 12 mg of product, which was dissolved in sterile
water (0.8 ml) at a concentration of 15 mg/ml.
Mass spectra and N-terminal amino acid sequence
analyses
The molecular weights of the purified elgicins were
determined by ESI-MS on a Thermo Finnigan LCQ
DECA XP MAX instrument (Thermo Electron Corpora-
tion, San Jose, CA). The electrospray source was oper-
ated at a capillary voltage of 17.49 V, a source voltage of
4.53 KV, and a capillary temperature of 275.10°C. The
mass spectra were measured in the range of 500-2000
m/z and analyzed using Xcalibur 1.4 software (Thermo
Electron Corporation). The N-terminal amino acid
sequence of the purified elgicin B was determined by an
automatic sequence analyzer (Gene Core Biotechnolo-
gies Co., Ltd., Shanghai, China) using the standard
Edman degradation method.
Assay of antimicrobial activity using the paper disk
method
The preparative RP-HPLC-purified elgicin compounds
were tested to determine their inhibitory spectra by the
paper disk diffusion method. Aliquots of overnight-cul-
tured test strains (100 μL) were spread using a glass rod
spreader on nutrient agar plates containing 2% agar. Ali-
quots (10 μL) of the elgicin compounds were pipetted
onto sterilized filter paper disks (0.6 cm in diameter),
which were then allowed to dry in an open 9-cm sterile
Petri dish at room temperature. The disks were placed
on the surface of the inoculated plates and incubated
for 18 h at 37°C. The diameters of the zone of inhibition
were measured. All analyses were conducted indepen-
dently in triplicate.
Nucleotide sequence accession number
T h ec o m p l e t en u c l e o t i d es e q u e n c eo ft h eelg gene clus-
ter derived in the present study was deposited in the
database of the National Center for Biotechnology Infor-
mation under accession number JQ429086.
Acknowledgements
The current work was supported by the Major State Basic Research
Development Program (973 Program, No. 2010CB833803). We thank Xinhang
Jiang, College of Life Sciences, Zhejiang University, for providing help with
the ESI-MS determinations.
Authors’ contributions
XCW and YT envisaged the study and designed the experiments. YT wrote
the manuscript and carried out the bioinformatic analysis. YT and WPZ
carried out the isolation and purification of the sample, and assayed
antibacterial activity. CDQ participated in the design of the study. XCW, OL,
and LZ helped to revise the manuscript. All authors read and approved the
final manuscript.
Received: 6 October 2011 Accepted: 26 March 2012
Published: 26 March 2012
References
1. Keymanesh K, Soltani S, Sardari S: Application of antimicrobial peptides in
agriculture and food industry. World J Microbiol Biotechnol 2009, 25(6):933-944.
2. Lubelski J, Rink R, Khusainov R, Moll GN, Kuipers OP: Biosynthesis,
immunity, regulation, mode of action and engineering of the model
lantibiotic nisin. Cellular and Molecular Life Sciences 2008, 65(3):455-476.
3. Kodani S, Hudson ME, Durrant MC, Buttner MJ, Nodwell JR, Willey JM: The
SapB morphogen is a lantibiotic-like peptide derived from the product
of the developmental gene ramS in Streptomyces coelicolor. Proc Natl
Acad Sci USA 2004, 101(31):11448-11453.
4. Engelke G, Gutowskieckel Z, Kiesau P, Siegers K, Hammelmann M,
Entian KD: Regulation of nisin biosynthesis and immunity in Lactococcus
lactis 6 F3. Appl Environ Microbiol 1994, 60(3):814-825.
5. Kuipers OP, Beerthuyzen MM, Siezen RJ, Devos WM: Characterization of
the nisin gene cluster nisABTCIPR of Lactococcus lactis, requirement of
expression of the nisA and nisI genes for development of immunity. Eur
J Biochem 1993, 216(1):281-291.
6. Meyer C, Bierbaum G, Heidrich C, Reis M, Suling J, Iglesiaswind MI,
Kempter C, Molitor E, Sahl HG: Nucleotide sequence of the lantibiotic
Pep5 biosynthetic gene cluster and functional analysis of PepP and
PepC, evidence for a role of PepC in thioether formation. Eur J Biochem
1995, 232(2):478-489.
7. Aso Y, Sashihara T, Nagao J, Kanemasa Y, Koga H, Hashimoto T, Higuchi T,
Adachi A, Nomiyama H, Ishizaki A, et al: Characterization of a gene cluster
of Staphylococcus warneri ISK-1 encoding the biosynthesis of and
immunity to the lantibiotic, nukacin ISK-1. Biosci Biotechnol Biochem 2004,
68(8):1663-1671.
8. Heidrich C, Pag U, Josten M, Metzger J, Jack RW, Bierbaum G, Jung G,
Sahl HG: Isolation, characterization, and heterologous expression of the
novel lantibiotic epicidin 280 and analysis of its biosynthetic gene
cluster. Appl Environ Microbiol 1998, 64(9):3140-3146.
9. Altena K, Guder A, Cramer C, Bierbaum G: Biosynthesis of the lantibiotic
mersacidin: organization of a type B lantibiotic gene cluster. Appl Environ
Microbiol 2000, 66(6):2565-2571.
10. Bierbaum G, Sahl HG: Lantibiotics: mode of action, biosynthesis and
bioengineering. Curr Pharm Biotechnol 2009, 10(1):2-18.
11. Nagao JI, Asaduzzaman SM, Aso Y, Okuda K, Nakayama J, Sonomoto K:
Lantibiotics: Insight and foresight for new paradigm. J Biosci Bioeng 2006,
102(3):139-149.
12. Stein T, Borchert S, Conrad B, Feesche J, Hofemeister B, Hofemeister J,
Entian KD: Two different lantibiotic-like peptides originate from the
ericin gene cluster of Bacillus subtilis A1/3. J Bacteriol 2002,
184(6):1703-1711.
13. Corvey C, Stein T, Dusterhus S, Karas M, Entian KD: Activation of subtilin
precursors by Bacillus subtilis extracellular serine proteases subtilisin
(AprE), WprA, and Vpr. Biochem Biophys Res Commun 2003, 304(1):48-54.
14. Daly KM, Upton M, Sandiford SK, Draper LA, Wescombe PA, Jack RW,
O’Connor PM, Rossney A, Gotz F, Hill C, et al: Production of the Bsa
lantibiotic by community-acquired Staphylococcus aureus strains. J
Bacteriol 2010, 192(4):1131-1142.
15. Cotter PD, Begley M, Hill C, Ross RP: Identification of a novel two-peptide
lantibiotic, Lichenicidin, following rational genome mining for LanM
proteins. Appl Environ Microbiol 2009, 75(17):5451-5460.
16. Li B, Sher D, Kelly L, Shi YX, Huang K, Knerr PJ, Joewono I, Rusch D,
Chisholm SW, van der Donk WA: Catalytic promiscuity in the biosynthesis
of cyclic peptide secondary metabolites in planktonic marine
cyanobacteria. Proc Natl Acad Sci USA 2010, 107(23):10430-10435.
17. Li JR, Beatty PK, Shah S, Jensen SE: Use of PCR-targeted mutagenesis to
disrupt production of fusaricidin-type antifungal antibiotics in
Paenibacillus polymyxa. Appl Environ Microbiol 2007, 73(11):3480-3489.
Teng et al. BMC Microbiology 2012, 12:45
http://www.biomedcentral.com/1471-2180/12/45
Page 8 of 918. Pichard B, Larue JP, Thouvenot D: Gavaserin and saltavalin, new peptide
antibiotics produced by Bacillus polymyxa. FEMS Microbiol Lett 1995,
133(3):215-218.
19. Wu XC, Shen XB, Ding R, Qian CD, Fang HH, Li O: Isolation and partial
characterization of antibiotics produced by Paenibacillus elgii B69. FEMS
Microbiol Lett 2010, 310(1):32-38.
20. Kim JF, Jeong H, Park SY, Kim SB, Park YK, Choi SK, Ryu CM, Hur CG,
Ghim SY, Oh TK, et al: Genome sequence of the polymyxin-producing
plant-probiotic rhizobacterium Paenibacillus polymyxa E681. J Bacteriol
2010, 192(22):6103-6104.
21. Ma MC, Wang CC, Ding YQ, Li L, Shen DL, Jiang X, Guan DW, Cao FM,
Chen HJ, Feng RH, et al: Complete genome sequence of Paenibacillus
polymyxa SC2, a strain of plant growth-promoting rhizobacterium with
broad-spectrum antimicrobial activity. J Bacteriol 2011, 193(1):311-312.
22. He ZG, Kisla D, Zhang LW, Yuan CH, Green-Church KB, Yousef AE: Isolation
and identification of a Paenibacillus polymyxa strain that coproduces a
novel lantibiotic and polymyxin. Appl Environ Microbiol 2007,
73(1):168-178.
23. Ding R, Li Y, Qian C, Wu X: Draft genome sequence of Paenibacillus elgii
B69, a strain with broad antimicrobial activity. J Bacteriol 2011,
193(17):4537.
24. Fuchs SW, Jaskolla TW, Bochmann S, Kotter P, Wichelhaus T, Karas M,
Stein T, Entian KD: Entianin, a novel subtilin-like lantibiotic from Bacillus
subtilis subsp spizizenii DSM 15029
T with high antimicrobial activity. Appl
Environ Microbiol 2011, 77(5):1698-1707.
25. Klein C, Kaletta C, Schnell N, Entian KD: Analysis of genes involved in
biosynthesis of the lantibiotic subtilin. Appl Environ Microbiol 1992,
58(1):132-142.
26. Immonen T, Ye S, Ra R, Qiao M, Paulin L, Saris PEJ: The codon usage of the
nisZ operon in Lactococcus lactis N8 suggests a non-lactococcal origin of
the conjugative nisin-sucrose transposon. DNA Seq 1995, 5(4):203-218.
27. Wirawan RE, Kleese NA, Jack RW, Tagg JR: Molecular and genetic
characterization of a novel nisin variant produced by Streptococcus
uberis. Appl Environ Microbiol 2006, 72(2):1148-1156.
28. Foulston LC, Bibb MJ: Microbisporicin gene cluster reveals unusual
features of lantibiotic biosynthesis in actinomycetes. Proc Natl Acad Sci
USA 2010, 107(30):13461-13466.
29. Widdick DA, Dodd HM, Barraille P, White J, Stein TH, Chater KF, Gasson MJ,
Bibb MJ: Cloning and engineering of the cinnamycin biosynthetic gene
cluster from Streptomyces cinnamoneus cinnamoneus DSM 40005. Proc
Natl Acad Sci USA 2003, 100(7):4316-4321.
30. Kabuki T, Kawai Y, Uenishi H, Seto Y, Kok J, Nakajima H, Saito T: Gene
cluster for biosynthesis of thermophilin 1277-a lantibiotic produced by
Streptococcus thermophilus SBT1277, and heterologous expression of
TepI, a novel immunity peptide. J Appl Microbiol 2011, 110(3):641-649.
31. Gutowski-Eckel Z, Klein C, Siegers K, Bohm K, Hammelmann M, Entian KD:
Growth phase-dependent regulation and membrane localization of
SpaB, a protein involved in biosynthesis of the lantibiotic subtilin. Appl
Environ Microbiol 1994, 60(1):1-11.
32. Asaduzzaman SM, Sonomoto K: Lantibiotics: diverse activities and unique
modes of action. J Biosci Bioeng 2009, 107(5):475-487.
33. Draper LA, Ross RP, Hill C, Cotter PD: Lantibiotic immunity. Curr Protein
Pept Sci 2008, 9(1):39-49.
34. Landy M, Warren GH, Rosenman SB, Colio LG: Bacillomycin: an antibiotic
from Bacillus subtilis active against pathogenic fungi. Proc Soc Exp Biol
Med 1948, 67(4):539-541.
35. Dingman DW, Stahly DP: Medium promoting sporulation of Bacillus
larvae and metabolism of medium components. Appl Environ Microbiol
1983, 46(4):860-869.
36. Tamura K, Dudley J, Nei M, Kumar S: MEGA4: Molecular Evolutionary
Genetics Analysis (MEGA) software version 4.0. Mol Biol Evol 2007,
24(8):1596-1599.
doi:10.1186/1471-2180-12-45
Cite this article as: Teng et al.: Gene Cluster Analysis for the
Biosynthesis of Elgicins, Novel Lantibiotics Produced by Paenibacillus
elgii B69. BMC Microbiology 2012 12:45.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Teng et al. BMC Microbiology 2012, 12:45
http://www.biomedcentral.com/1471-2180/12/45
Page 9 of 9